Development and Validation of UV Spectrophotometric Method for Estimation Ibandronate sodium in Pharmaceutical Formulation by Chawale, Prajakta A. et al.
Prajakta et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(3):339-343 
ISSN: 2250-1177                                                                                  [339]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.05.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Development and Validation of UV Spectrophotometric Method for 
Estimation Ibandronate sodium in Pharmaceutical Formulation 
Prajakta A. Chawale, Dinesh R. Chaple, Alpana J. Asnani, Kumar Pratyush 
Priyadarshini J. L. College of Pharmacy, Electronic zone, Electronic building, Hingna Road, Nagpur-440016 
 
ABSTRACT 
A simple, accurate, precise, rapid spectrophotometric method for estimation of Ibandronate sodium in pharmaceutical formulation. 
Ibandronate sodium is one off the nitrogen carrying bisphosphonate. It prevents osteoclast-conciliate bone resorption, Paget’s disease, 
postmenopausal osteoporosis. The maximum wavelength (λmax) of ibandronate sodium is 218nm. Linearity was observed in the conc entration 
range 2-100µg/ml. The coefficient of variation value was found to be 0.3499. Amount of drug estimated from tablet formulation were in precise 
with label claim. The method was statistically validated as per ICH guidelines and can be successively applied for analysis for tablet formulation. 
The proposed method is economical and sensitive for estimation of ibandronate sodium in pharmaceutical formulation.  
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INTRODUCTION 
Bisphosphonates are a class of drugs that prevent the loss 
of bone density, used to treat osteoporosis and similar 
diseases. They are the most commonly prescribed drugs 
used to treat osteoporosis. They are called bisphosphonates 
because they have two phosphonates (PO(OH)2) groups. 
They are thus also called diphosphonates. Ibandronate 
sodium is one of the nitrogen carrying bisphosphonate.[13] 
According to IUPAC nomenclature it is 3-(N-methyl-N-
pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid, 
sodium salt, monohydrate with the molecular formula 
C9H22NO7P2Na.H2O and molecular weight of 359.23. It 
prevents osteoclast-conciliate bone resorption.[16] It is 
precious for the cure of hypercalcemia of malignancy, Paget's 
disease, postmenopausal osteoporosis, and corticosteroid-
induced osteoporosis metastatic bone disease. The activity of 
ibandronate on bone tissue is depending on its resemblance 
for hydroxyapatite, which is fraction of the mineral matrix of 
bone. In postmenopausal women, it decreases the high rate 
of bone mass, leading to, a net gain in bone mass.[15] For 
quantification of impurity and assay of ibandronate sodium, 
there are so many analytical methods have been determined. 
The aim of our study was to develop an easy responsive 
accurate and precise method for determination of 
ibandronate sodium in pharmaceutical formulations and 
bulk drugs using UV spectrophotometer. 
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Fig.1 Structure of Ibandronate sodium 
 
MATERIALS AND METHODS 
Ibandronate sodium drug (Batch No. IBS/07/11) was 
obtained from JPN pharma Pvt Ltd, Mumbai. Shimadzu UV 
Visible Spectro- photometer (UV-1800) with asynchronized 
pair of 10 mm quartz cells were used for experimental 
reason. 
1. Selection of Solvent 
0.1N NaOH was selected as the suitable solvent for 
estimation of Ibandronate sodium after several trails. 
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2. Standard Stock Solution 
An accurately weighed quantity of Ibandronate 
sodium(10.0mg) was dissolved in 0.1N NaOH in volumetric 
flask(10.0ml). The volume was made up to mark with 0.1N 
NaOH. Appropriate dilutions were made from resulting 
solution with NaOH so as to get a concentration of 10 µg/ml. 
3.   Selection of Maximum wavelength (λ max) 
Solution was scanned within the wavelength region of 200-
400nm against NaOH as blank using UV spectrophotometer. 
At 218 nm of Ibandronate sodium maximum absorption in 
absorption curve. 
 
 
Fig no.2 UV Spectra of Ibandronate sodium 
 
Determination of A(1%.1cm) value of Ibandronate sodium at 218nm A(1%,1cm) = Absorbance/ Concentration 
(g/100ml) 
Table no.1 Result of A1%,1cm. 
   Sr.no       Concentration      Absorbance              A1% 
   1            10µg/ml      0.155nm             155 
   2            10µg/ml      0.153nm              153 
   3            10µg/ml      0.149nm              149 
   4            10µg/ml      0.152nm              152 
   5            10µg/ml      0.158nm               158 
 
Table no.2 Statistical Data 
 Mean 153.4 
Standard deviation 0.9992 
Relative standard deviation 0.6513 
 
Application of Proposed Method to Marketed 
Formulation 
Twenty tablets were weighed, calculate average weight and 
powdered. An amount of tablet powdered equivalent to 10 
mg of Ibandronate sodium was weighed accurately and 
transferred to a 10 ml of NaOH in volumetric flask and 
sonicated for 15 min and then diluted up to the mark with 
NaOH. The resultant solution was again diluted by 0.1N 
NaOH to get concentration 10 µg/ml. The absorbance was 
measured at selected wavelength 218nm and concentration 
of the sample present in marketed formulation was 
determined.   
Average weight of tablet=0.601g            
                                                                                                                                                                                                                                                   
Table no.3 Result of assay of tablet 
Sr.no Amount of tablet powder taken(g) Amount of drug estimated(g) % labelled claim 
1 0.0402g 0.149 99.33 
2 0.0400g 0.148 98.66 
3 0.0401g 0.151 100.66 
4 0.0403g 0.146 97.33 
5 0.0401g 0.147 98.00 
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Table no.4 Statistical Data 
 Mean 98.79 
Standard deviation 1.1436 
Relative standard deviation 1.1576 
Method Validation 
Validation is one of the important steps for analytical 
determination of any drug. There is a number of most 
significant validation parameters such as linearity and range, 
accuracy and precision, LOD, LOQ, recovery, ruggedness, 
robustness were assessed in developed method. 
Linearity and Range 
Standard solution was prepared by daily diluting stock 
solution with NaOH. To get calibration standard solutions 
2,5,10,20,30,40,50,60,70,80,90,100 µg /ml of Ibandronate 
sodium to construct Beers law plot for pure drug. The range 
of drug to study the Beers law is 2-100µg/ml. A calibration 
curve was plotted as concentration verses absorbance. 
Accuracy 
Accuracy of the method was determined by replicate 
analysis of three sets of samples spiked with three different 
levels of Ibandronate sodium at level 80%, 100% and 120% 
and comparing the difference between the spiked value 
(theoretical value) and that actually found value 
Precision 
The precision of the method based on the study of 
ruggedness was carried out under different conditions. 
 Limit of detection (LOD) and Limit of quantification 
(LOQ) 
The method is used based on standard deviation of the 
response and slope of calibration curve. 
The formula is 
                 LOD=3.3σ          LOQ= 10σ 
                              S                            S 
Signal to noise ratio (k)=3.3 and 10 for LOD and LOQ 
respectively     
σ  = standard deviation of the response ,  
S = Slope of the calibration curve 
RESULTS AND DISSCUSSION 
Validation is one of the important steps for analytical 
determination of any drug. There is a number of most 
significant validation parameters such as linearity and range, 
accuracy and precision, LOD, LOQ, recovery, ruggedness, 
robustness were assessed in developed method.[20] 
Linearity and Range 
Standard solution was prepared by daily diluting stock 
solution with NaOH. To get calibration standard solutions 
2,5,10,20,30,40,50,60,70,80,90,100 µg /ml of Ibandronate 
sodium to construct Beers law plot for pure drug. The range 
of drug to study the Beers law is 2-100µg/ml. A calibration 
curve was plotted as concentration verses absorbance. 
 
Fig. 3 Calibration curve of Ibandronate sodium 
Accuracy 
Accuracy of the method was determined by replicate 
analysis of three sets of samples spiked with three different 
levels of Ibandronate sodium at level 80%, 100% and 120% 
and comparing the difference between the spiked value 
(theoretical value) and that actually found value.
 
Table no.5 Results of recovery studies 
Sr.no. Amount of pure drug 
added 
Amount of sample 
added 
Amount of drug 
recovered 
% Drug recovery 
                                                                    80 % recovery 
1 40 50 39.85 99.62 
2 40 50 39.91 99.77 
3 40 50 39.98 99.95 
   100 % recovery 
1 50 50 49.96 97.92 
2 50 50 49.81 99.62 
3 50 50 49.89 99.78 
                                                                    120% recovery 
1 60 50 58.91 98.18 
2 60 50 59.49 99.15 
3 60 50 59.98 99.96 
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Table.no 6 Statistical data 
        Mean            Standard deviation 
 
 Relative standard deviation 
80 % recovery 
       99.78           0.11545        0.11570 
100 % recovery 
       99.10          0.84063        0.84826 
120 % recovery 
       99.09           0.72341        0.73005 
 
Precision 
The precision of the method based on the study of ruggedness was carried out under different conditions. 
Table no.7    Result of Intraday 
    Time Amount of tablet powdered taken (g)  Amount of drug estimated (g) % Drug estimated  
     0hr          0.0401        0.151         100.66 
     3hr          0.0400        0.150         100.00 
     6hr          0.0402         0.149          99.33 
 
Table no.8 Statistical data 
           Drug             Mean    Standard Deviation Relative standard deviation        
Ibandronate sodium       99.33            0.8563           0.8620 
 
Table no.9 Result of Interday 
     Day 
 
Amount of tablet powdered taken (g) Amount of drug estimated (g) % labeled 
claim 
      Day1    0.0405       0.149    99.33 
     Day2    0.0406       0.148     98.66 
     Day3     0.0400       0.146      97.33 
 
Table no.10 Statistical data 
           Drug            Mean      Standard Deviation   Relative standard deviation        
    Ibandronate sodium           98.44             0.8246         0.8376 
 
 
Limit of detection (LOD) and Limit of quantification (LOQ) 
The LOD and LOQ are given in Table no 12. 
Table no.11 Result of LOD and LOQ 
             PARAMETERS                  IBANDRONATE SODIUM 
           LOD(µg/ml)              0.56943 
           LOQ(µg/ml)             1.72551 
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CONCLUSION 
Simple, accurate, precise, sensitive spectrometric method 
was done for the estimation of Ibandronate sodium in 
pharmaceutical formulation. 
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